Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Emeralda Burke-Murphy"'
Autor:
Jeannie Callum, Darinka Sakac, Nagina Parmar, Yulia Lin, Katerina Pavenski, Qi-Long Yi, Tik Nga Tong, Lani Lieberman, Jacob Pendergrast, Christine Cserti-Gazdewich, Donald R. Branch, Megan Blacquiere, Wendy Lau, Nadine Shehata, Emeralda Burke-Murphy
Publikováno v:
Transfusion. 60:3010-3018
Background Hemolysis following the administration of intravenous immunoglobulin (IVIG) is an important adverse event (AE). While the monocyte monolayer assay (MMA) has been used to predict in vivo hemolysis when serologically incompatible blood may b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a767c7da2c52b549f00e393acc6f18
https://doi.org/10.1111/trf.16131
https://doi.org/10.1111/trf.16131
Autor:
Lani Lieberman, Beth Binnington, Nadine Shehata, Donald R. Branch, Emeralda Burke-Murphy, Jacob Pendergrast, Barbara Hannach, Katerina Pavenski, Vincent Laroche, Megan Blacquiere, Yulia Lin, Kezia Willie, Jiwajee Aziz, Jeannie Callum, Wendy Lau, Christine Cserti-Gazdewich, Jill R. Storry, Lorna Sampson Riden, Åsa Hellberg, Christine W. Bruggeman, Nagina Parmar, Darinka Sakac, Tik Nga Tong, Chantal Armali, Taco W. Kuijpers, Martin L. Olsson
Publikováno v:
Blood, 131(7), 830-835. American Society of Hematology
TO THE EDITOR: Although frequently effective[1][1],[2][2] and usually benign, high-dose (2 g/kg) intravenous immunoglobulin (IVIG) therapy can result in marked red blood cell (RBC) hemolysis, which in some cases is life threatening in severity.[3][3]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c37423ab83f22e46565f0e7c728f0fac
https://doi.org/10.1182/blood-2017-07-796151
https://doi.org/10.1182/blood-2017-07-796151
Autor:
Donald R. Branch, Emeralda Burke-Murphy, Darinka Sakac, Vincent Laroche, Christine Cserti-Gazdewich, Jacob Pendergrast, Tik Nga Tong
Publikováno v:
Transfusion. 56:2680-2690
BACKGROUND Various versions of the monocyte monolayer assay (MMA) have been used to assess clinical significance of red blood cell (RBC) alloantibodies in transfusion for more than 35 years. However, the optimal conditions, including anticoagulant us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7528913eead5d86364a2193415989700
https://doi.org/10.1111/trf.13766
https://doi.org/10.1111/trf.13766
Autor:
Tik Nga, Tong, Emeralda, Burke-Murphy, Darinka, Sakac, Jacob, Pendergrast, Christine, Cserti-Gazdewich, Vincent, Laroche, Donald R, Branch
Publikováno v:
Transfusion. 56(11)
Various versions of the monocyte monolayer assay (MMA) have been used to assess clinical significance of red blood cell (RBC) alloantibodies in transfusion for more than 35 years. However, the optimal conditions, including anticoagulant used for whol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9698132f9e566aea2bbf316c3360aa62
https://pubmed.ncbi.nlm.nih.gov/27546234
https://pubmed.ncbi.nlm.nih.gov/27546234
